The Vector Center, which has released the Russian vaccines against the coronavirus EpiVacCorona and EpiVacCorona-N, is ready to transfer the technology for the production of the second drug abroad. According to the developer, this vaccine is ideal for mass production.
“EpiVacCorona-N is our response to the growing demand for means of preventing coronavirus infection. The vaccine has technological features of production that provide significant scaling, “- said the developers of” Komsomolskaya Pravda “.
In addition to Vector, EpiVacCoron will be produced by Vector-Bialgam, Geropharm and others, the center said. “Vector” is ready to provide technology of production of “EpiVacKorona-N” not only to Russian, but also to foreign partners, the message says.
The Novosibirsk center “Vector” filed an application for registration of “EpiVacKorona-N” on June 28. According to the card in the state register of medicines, this is a drug based on peptide antigens. The dosage form is a suspension for intramuscular administration, the volume of one dose is 0.5 ml.
Earlier, the Ministry of Health issued permission to conduct the first and second phases of clinical trials of EpiVacKorona-N. The main drug of the Vector Center, EpiVacCorona, was the second Russian vaccine registered in Russia (in October 2020). In addition to it, the country approved the use of the Sputnik V vaccine of the Gamaleya Center, its one-component version Sputnik Light and the CoviVac of the Chumakov Center.
About testing the first vaccine “Vector” – in the material “Kommersant” “EpiVacKorona” was tested on volunteers and primates. “
.